The KATY System: From Research Pilot to Medical Practice
KATY is an intuitive and user-friendly platform that is designed to enhance communication between patients and clinicians in the context of renal cancer treatment.
The web application combines a well-designed user interface with complex medical data. Based on explainable artificial intelligence – AI whose decisions are transparent, trustworthy, and traceable – it can assign patients to a specific treatment path and reduce unnecessary treatment lines. To achieve this, the software compares patients’ individual medical data – including genomic information, demographic factors, comorbidities and therapy history – with a large dataset on kidney cancer responses to targeted therapies. Subsequently, it predicts the success rates of different treatment scenarios.
The KATY system supports informed decision-making by patients in collaboration with their clinicians. It empowers patients by making medical information more accessible and facilitates collaborative approaches to healthcare. The tool fosters a more patient-centric healthcare that improves patient’s quality of life and ensures manageable incremental costs at the same time.
What functions does the software provide?
KATY combines an AI-powered therapy recommendation service with a knowledge graph, a centralized repository of biomedical knowledge. Users can upload and download patients’ genomic data, which can subsequently be used to generate therapy recommendations. After selecting a combination of drugs and genes, the tool displays a recommended therapy, an associated score, and estimated survival rates. The current version of the KATY platform is available for desktop computers and tablets.
Is it already possible to register?
The platform is currently available in a preliminary version. Both clinicians and researchers may already register for access. KATY provides role-based user accounts: clinicians can request therapy generation, whereas researchers are granted access to therapy data previously generated by clinicians. You can access the platform via https://katyplatform.eu.
For more information or to request an account, please contact Riccardo Leoni.
What comes next?
Reusability and integration capability were two key objectives that guided software development from the start of the project. The project team is actively exploring open-source licensing models for selected components. In this way, the consortium aims to promote adoption of the software to encourage uptake by external research groups, healthcare providers, and technology developers in the post-project phase. Making the software accessible and usable for a large number of researchers and clinicians is a future endeavour of the consortium partners.
